Physician profile
Alain Alvarez
NPI 1841457496
$34,498.37
in general payments reported to CMS, 2019-2025
42 companies · $4,463 in 2025
The $4,463 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,303 · 2020: $4,190 · 2021: $4,983 · 2022: $5,510 · 2023: $7,226 · 2024: $4,823 · 2025: $4,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Honoraria: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,710.99 |
| Honoraria | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,680.07 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $5,252.67 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $3,292.09 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $2,850.30 | 2019-2023 | Krystexxa, Tepezza |
| Genzyme Corporation | $2,551.45 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,374.98 | 2019-2025 | |
| Ucb, INC. | $2,111.02 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,499.25 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,042.71 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $948.57 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $908.48 | 2020-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $775.73 | 2022-2025 | Tremfya |
| Pfizer INC. | $751.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $630.68 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.33 | 2019-2024 | Cyltezo, Ofev |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $312.88 | 2019 | |
| Genentech, INC. | $287.70 | 2020 | |
| Radius Health, INC. | $269.74 | 2020-2025 | Tymlos |
| Genentech USA, INC. | $176.76 | 2019-2023 | Ocrevus |
| Fresenius Kabi USA, LLC | $145.64 | 2023-2024 | Idacio |
| Celgene Corporation | $136.95 | 2019 | |
| Pacira Therapeutics, INC. | $120.34 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $112.24 | 2021-2025 | Lupkynis |
| Fidia Pharma USA INC. | $108.72 | 2020-2023 | Hymovis, Triluron |
| Antares Pharma, INC. | $94.77 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $92.68 | 2019 | |
| Sobi, INC | $83.16 | 2019-2023 | |
| Almatica Pharma LLC | $55.33 | 2024-2025 | Teriparatide |
| Alvogen INC | $51.82 | 2021-2022 | |
| Biocon Biologics INC | $48.00 | 2024-2025 | Hulio, Yesintek |
| Sandoz INC. | $35.64 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $32.96 | 2020-2025 | Strensiq |
| Organon LLC | $31.33 | 2024 | |
| Mylan Institutional INC. | $24.01 | 2023 | Hulio |
| Pacira Pharmaceuticals Incorporated | $22.48 | 2023 | Zilretta, Iovera |
| Ultragenyx Pharmaceutical INC. | $20.85 | 2024 | Crysvita |
| Cumberland Pharmaceuticals, INC. | $19.41 | 2022 | |
| Nevro Corp. | $19.17 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $17.94 | 2024 | Simlandi |
| Ani Pharmaceuticals, INC. | $17.15 | 2022 | |
| Merck Sharp & Dohme LLC | $15.69 | 2019 | |
| Medexus Pharma, INC. | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alain Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.